Suppliers / Norgine Healthcare

Norgine Healthcare

United Kingdom 37 employees Updated 9 July 2026

Norgine Healthcare is a finished-dose manufacturer based in United Kingdom. It appears in 480 regulatory filings across 18 regulators, without an active US DMF or CEP on file. Its filings concentrate with EMA, MHRA (UK) and AIFA (IT). Its GMP standing is certified by MHRA (UK), US FDA and EMA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 20 June 2025 as VAI.

0
active US DMFs
0
valid CEPs
6
registered plants 1 with an FDA FEI number
480
filings across 18 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 20 June 2025 VAI US FDA
  • 16 August 2019 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Hengoed, United Arab Emirates Not on file
Luzern, Switzerland Not on file
NEWPORT, United Kingdom Not on file
HENGOED, United Kingdom Not on file
United Kingdom, United Kingdom 3005202761
Amsterdam, Netherlands Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA 121 1
MHRA (UK) 108 5
AIFA (IT) 78 None
SWISSMEDIC (CH) 36 None
AEMPS (ES) 27 None
FAMHP (BE) 24 None
US FDA None 1
EAEU_EEC None 1

Comparing suppliers?

Choose your molecules and target markets. Norgine Healthcare comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 20 June 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates